Latest news with #BSX
Reuters
6 days ago
- Business
- Reuters
Boston Scientific to stop heart device sales, not seek new approvals
May 28 (Reuters) - Boston Scientific (BSX.N), opens new tab said on Wednesday it has stopped global sales of its heart device and will not seek approval in geographies it is not yet available due to increased clinical and regulatory requirements. Shares of the device maker fell 1.5% to $104.57 in premarket trading. The devices, called transcatheter aortic valve replacement (TAVR), had obtained the European Union's CE-mark and were sold under the brands Acurate Prime and Acurate neo2 for minimally invasive heart surgeries. But the company said recent discussions with U.S. and other regulators resulted in increased requirements to maintain regulatory approvals in existing and new markets. "The resources and investments necessary to meet these new requirements are prohibitive," the company said. The company expects to meet second quarter and full-year outlook despite the anticipated financial hit from the decision, Boston said, adding that it has not reaffirmed the outlook.
Yahoo
24-05-2025
- Business
- Yahoo
Was Jim Cramer Right About Boston Scientific Corporation (BSX)?
We recently published a list of . In this article, we are going to take a look at where Boston Scientific Corporation (NYSE:BSX) stands against other stocks that Jim Cramer discusses. Back in 2024, on May 16, a caller asked about Boston Scientific Corporation (NYSE:BSX), a medical device company. Cramer praised its cardio business and wished he had bought it back then: 'That company is just doing so well. They have an amazing cardio franchise. I wish I owned that for the trust. It is just fantastic. Great call — thank you.' A surgeon examining a patient's brain in an operating room, paramedics nearby. Boston Scientific was a clear win for Cramer, rising 42.24% on the back of strong fundamentals. Boston Scientific Corporation (NYSE:BSX) is thriving thanks to a strong product pipeline in cardiology and minimally invasive surgery. Overall, BSX ranks 4th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Here's How Much You'd Have If You Invested $1000 in Boston Scientific a Decade Ago
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks. What if you'd invested in Boston Scientific (BSX) ten years ago? It may not have been easy to hold on to BSX for all that time, but if you did, how much would your investment be worth today? With that in mind, let's take a look at Boston Scientific's main business drivers. Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific reorganized its operational structure and aggregated its core businesses, each of which generates revenues from the sale of Medical Devices, into two reportable segments, MedSurg (35.8% of total revenue; 2024 organic growth was 7.5% over 2023) and Cardiovascular (accounting for the rest; 21.9% organic growth in 2024). The Cardiovascular segment coprises Cardiology division (represents the combined former Rhythm Management and Interventional Cardiology businesses) and Peripheral Interventions. MedSurg group comprises 3 sub segments, viz. Endoscopy; Urology; and Neuromodulation. The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. In addition, in Europe, it markets the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System featuring an ultra-thin abluminal (outer) bioabsorbable polymer coating. The company also markets balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures, as well as intravascular ultrasound (IVUS) imaging systems. Anyone can invest, but building a successful investment portfolio requires research, patience, and a little bit of risk. So, if you had invested in Boston Scientific ten years ago, you're likely feeling pretty good about your investment today. A $1000 investment made in May 2015 would be worth $5,925.47, or a gain of 492.55%, as of May 21, 2025, according to our calculations. This return excludes dividends but includes price appreciation. The S&P 500 rose 179.44% and the price of gold increased 162.41% over the same time frame in comparison. Going forward, analysts are expecting more upside for BSX. Despite macroeconomic issues, primarily the tariff tension, and related cost inflation, Boston Scientific is seeing strength across target markets. Strong worldwide demand for its MedSurg and Cardiovascular lines, traction in United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important drivers. The Pain and Brain franchisees are gaining solid traction in 2025 banking on strong execution of core growth strategies. The Electrophysiology arm continues to gain momentum on sustained adoption of FARAPULSE PFA. The 2025 guidance indicating strong organic growth over 2024 builds confidence in the stock. On the flip side, mounting costs due to worldwide geopolitical issues are major concerns. FX headwinds are expected to impact the company's top line in 2025. Shares have gained 12.09% over the past four weeks and there have been 11 higher earnings estimate revisions for fiscal 2025 compared to none lower. The consensus estimate has moved up as well. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Why Boston Scientific Corporation (BSX) Is Among the Best Medical Device Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where Boston Scientific Corporation (NYSE:BSX) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president's newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back. The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation: 'MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.' Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined: 'The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump's second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices. Casey Hite, CEO of Aeroflow Health, a firm that provides insurance-covered medical devices, said the following: 'With the level of tariffs that we're looking at in China, businesses are going to be completely upside down on these products … they can't pass those costs on to the consumer. I think what we would like to see, more than anything, is a runway or some predictability. Let's do this over the next 12 months, next two years, so that US organizations can prepare.' We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best medical device stocks and then chose the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A surgeon examining a patient's brain in an operating room, paramedics nearby. Number of Hedge Fund Holders: 96 Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation. The company ranks fourth on our list of the top medical device stocks to invest in. On April 25, Barclays analyst Matt Miksic raised the firm's price target on Boston Scientific Corporation (NYSE:BSX) to $125 from $118, keeping an Overweight rating on the shares. The firm reasoned that solid results from ADVANTAGE-AF for using Farawave and Farapoint in persistent atrial fibrillation should allow FDA approval later this year. BTIG analyst Marie Thibault also maintained their bullish stance on the stock on April 23, giving it a buy rating based on its solid financial performance and promising outlook. Boston Scientific Corporation (NYSE:BSX) reported notable fiscal Q1 2025 revenue and EPS, surpassing both market expectations and its own guidance. The analyst attributed this success to higher-than-expected sales in electrophysiology and interventional cardiology. This holds especially true for the Farapulse franchise, which has positioned the company as a leader in the electrophysiology market. Boston Scientific Corporation (NYSE:BSX) has raised its 2025 revenue guidance, and the upcoming CFO transition is expected to maintain stability in leadership, reflecting confidence in its stable growth and sustained profitability. Overall, BSX ranks 4th on our list of the best medical device stocks to buy now. While we acknowledge the potential for BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BSX but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
10-05-2025
- Business
- Yahoo
Possible Bearish Signals With Boston Scientific Insiders Disposing Stock
Many Boston Scientific Corporation (NYSE:BSX) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Over the last year, we can see that the biggest insider sale was by the Lead Independent Director, Edward Ludwig, for US$1.3m worth of shares, at about US$105 per share. So we know that an insider sold shares at around the present share price of US$103. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. We note that this sale took place at around the current price, so it isn't a major concern, though it's hardly a good sign. In total, Boston Scientific insiders sold more than they bought over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! View our latest analysis for Boston Scientific For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket. The last three months saw significant insider selling at Boston Scientific. In total, Lead Independent Director Edward Ludwig dumped US$1.3m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain. Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that Boston Scientific insiders own 0.2% of the company, worth about US$281m. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders. An insider hasn't bought Boston Scientific stock in the last three months, but there was some selling. Despite some insider buying, the longer term picture doesn't make us feel much more positive. But since Boston Scientific is profitable and growing, we're not too worried by this. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Boston Scientific. Case in point: We've spotted 2 warning signs for Boston Scientific you should be aware of. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
